Phase-II Trial with Ifosfamide/Mesna 24 h Intravenously for the Treatment of Advanced Cancer of the Cervix

Publisher Website
Google Scholar
Abstract
SummaryThis study was carried out to assess the efficacy of ifosfamide/mesna in the treatment of advanced or recurrent cancer of the cervix. From July 1982 to October 1985, we treated 21 patients with advanced or non-operable cancer of the cervix. All 21 patients were evaluable. The mean age was 55 (range 32–69 years); Stage III: 13 patients, and stage IV: 8 patients, according to FIGO. Karnofsky scale ranged between 50 and 90, with a median of 70. Metastases were located in lung (2), bladder (3), liver (2) and vulvar (1). Patients were treated previously with surgery (2), radium (9) and cobalt 60 (11). Patients were treated with ifosfamide/mesna (5 g/m2 24-h infusion on day 1, every 4 weeks) and cis-platinum (20 mg/m2 i.v. on days 1–3). For evaluation purposes, patients received at least 2 cycles. Toxicity was registered in 69 cycles and ranged from mild to severe: anemia (18), leukopenia (6), nausea and vomiting (21), alopecia (18), creatinine > 1.2 mg% (3), microscopic hematuria (1), increased transaminase (1). No CNS symptoms were registered. One complete (4.8%) and 9 partial (42.8%) responses were observed (47.6%). The median duration of response was 60 weeks; the overall median survival time was 65 weeks; 150 weeks for responders and 40 weeks for non-responders. The results of this study indicate that ifosfamide plus cis-platinum are synergistic in the treatment of cancer of the cervix.

This publication has 0 references indexed in Scilit: